naltrexone and incretins

naltrexone has been researched along with incretins in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Aronne, LJ	1
Nadolsky, KZ	1
Barakat, M; Blavignac, J; Burrows, M; Camacho, F; Christensen, RAG; Gould, E; Kamran, E; Wharton, S; Yin, P	1

Reviews

1 review(s) available for naltrexone and incretins

Article	Year
Evolving directions in obesity management. The Journal of family practice, 2014, Volume: 63, Issue:7 Suppl Topics: Anti-Obesity Agents; Bupropion; Dopamine Uptake Inhibitors; Forecasting; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Liraglutide; Naltrexone; Narcotic Antagonists; Obesity; Receptors, Glucagon	2014

Other Studies

2 other study(ies) available for naltrexone and incretins

Article	Year
Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population. Military medicine, 2018, 03-01, Volume: 183, Issue:3-4 Topics: Alcohol Deterrents; Appetite Depressants; Benzazepines; Cohort Studies; Drug Therapy; Humans; Incretins; Liraglutide; Military Personnel; Naltrexone; Obesity; Phentermine; Retrospective Studies	2018
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial. International journal of obesity (2005), 2021, Volume: 45, Issue:8 Topics: Aged; Anti-Obesity Agents; Body Weight; Bupropion; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incretins; Male; Middle Aged; Naltrexone; Obesity; Randomized Controlled Trials as Topic; Weight Loss	2021

Article

Year

Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population.

Military medicine, 2018, 03-01, Volume: 183, Issue:3-4

Topics: Alcohol Deterrents; Appetite Depressants; Benzazepines; Cohort Studies; Drug Therapy; Humans; Incretins; Liraglutide; Military Personnel; Naltrexone; Obesity; Phentermine; Retrospective Studies

2018

Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.

International journal of obesity (2005), 2021, Volume: 45, Issue:8

Topics: Aged; Anti-Obesity Agents; Body Weight; Bupropion; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incretins; Male; Middle Aged; Naltrexone; Obesity; Randomized Controlled Trials as Topic; Weight Loss

2021